PATENTS/TRADE SECRETS In/Sight
Stephen Friend, of Sage Bionetworks, writes about the need for more collaborative drug development models. He quotes Tania Bubela, of the University of Alberta, who succintly makes the point that “Patenting is inversely correlated with academic collaboration”.
90 percent of Phase II drug trials fail. “Failure” sometimes includes causing unanticipated harm to patients.
The author’s thesis is that a sharing of information would prevent a lot of these misadventures. Drug trials are both hazardous to patients and costly to drug development companies and to the economy generally. In addition, a great deal of repetitious research would be obviated by sharing rather than hoarding information in the hope of obtaining patent protection.
Click on the tile above to read the article “Crowdsourcing Drug Discovery”.
suite 1400 - 439 university avenue , toronto, ontario m5g 1y8 , tel: 416-408-4565 begin_of_the_skype_highlighting 416-408-4565 end_of_the_skype_highlighting x 224 , fax: 416-408-4569 www.ludlowlaw.ca
